The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its ...